Who are CEM-101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vorinostat (VOR), Chidamide+ Fulvestrant, SHR2554; Chidamide analog tablets, HLD200, VDPHL01 QD, VDPHL01.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cem-101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

CEM-101 — Competitive Intelligence Brief

CEM-101 (CEM-101) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HDAC inhibitor. Area: Oncology.

phase 2 HDAC inhibitor HDAC6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CEM-101 (CEM-101) — Melinta Therapeutics, Inc.. CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CEM-101 TARGET	CEM-101	Melinta Therapeutics, Inc.	phase 2	HDAC inhibitor	HDAC6
Vorinostat (VOR)	Vorinostat (VOR)	University of North Carolina, Chapel Hill	marketed	Histone deacetylase (HDAC) inhibitor	Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8)
Chidamide+ Fulvestrant	Chidamide+ Fulvestrant	Liaoning Cancer Hospital & Institute	marketed	HDAC inhibitor + selective estrogen receptor degrader (combination therapy)	Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα)
SHR2554; Chidamide analog tablets	SHR2554; Chidamide analog tablets	Jiangsu HengRui Medicine Co., Ltd.	phase 3	HDAC inhibitor	HDAC
HLD200	HLD200	Ironshore Pharmaceuticals and Development, Inc	phase 3	HDAC inhibitor	Histone deacetylase (HDAC)
VDPHL01 QD	VDPHL01 QD	Veradermics, Inc.	phase 3	HDAC inhibitor	H3 histone deacetylase (HDAC)
VDPHL01	VDPHL01	Veradermics, Inc.	phase 3	HDAC inhibitor	H3 histone deacetylase (HDAC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HDAC inhibitor class)

Veradermics, Inc. · 2 drugs in this class
Ironshore Pharmaceuticals and Development, Inc · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Melinta Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CEM-101 — Competitive Intelligence Brief. https://druglandscape.com/ci/cem-101. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab